Millennium Management LLC Grows Stock Position in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)

Millennium Management LLC raised its position in shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Free Report) by 22.7% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 896,987 shares of the biotechnology company's stock after buying an additional 165,692 shares during the quarter. Millennium Management LLC owned about 4.21% of Enanta Pharmaceuticals worth $5,158,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in the company. AlphaQuest LLC grew its position in Enanta Pharmaceuticals by 16.4% in the fourth quarter. AlphaQuest LLC now owns 22,260 shares of the biotechnology company's stock worth $128,000 after acquiring an additional 3,137 shares in the last quarter. Jacobs Levy Equity Management Inc. lifted its stake in shares of Enanta Pharmaceuticals by 51.3% in the 4th quarter. Jacobs Levy Equity Management Inc. now owns 290,011 shares of the biotechnology company's stock valued at $1,668,000 after purchasing an additional 98,285 shares during the last quarter. Thrivent Financial for Lutherans purchased a new position in shares of Enanta Pharmaceuticals in the 4th quarter worth approximately $254,000. Marshall Wace LLP increased its position in shares of Enanta Pharmaceuticals by 9.3% during the 4th quarter. Marshall Wace LLP now owns 930,087 shares of the biotechnology company's stock valued at $5,348,000 after purchasing an additional 79,197 shares during the last quarter. Finally, Norges Bank purchased a new stake in Enanta Pharmaceuticals during the 4th quarter valued at $234,000. Institutional investors own 94.99% of the company's stock.

Enanta Pharmaceuticals Price Performance

NASDAQ:ENTA traded down $0.19 during midday trading on Friday, hitting $5.97. The company's stock had a trading volume of 176,864 shares, compared to its average volume of 285,101. Enanta Pharmaceuticals, Inc. has a fifty-two week low of $4.09 and a fifty-two week high of $17.24. The firm has a market cap of $127.62 million, a P/E ratio of -1.21 and a beta of 0.81. The firm's 50 day moving average is $5.39 and its 200-day moving average is $6.32.

Enanta Pharmaceuticals (NASDAQ:ENTA - Get Free Report) last posted its earnings results on Monday, May 12th. The biotechnology company reported ($1.06) EPS for the quarter, missing the consensus estimate of ($1.04) by ($0.02). The company had revenue of $14.93 million for the quarter, compared to analyst estimates of $15.96 million. Enanta Pharmaceuticals had a negative return on equity of 75.53% and a negative net margin of 157.57%. As a group, analysts forecast that Enanta Pharmaceuticals, Inc. will post -4.65 EPS for the current year.

Analyst Ratings Changes

A number of research firms recently weighed in on ENTA. JMP Securities reissued a "market outperform" rating and issued a $21.00 price objective on shares of Enanta Pharmaceuticals in a research report on Tuesday, February 11th. Wall Street Zen upgraded Enanta Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Wednesday, February 19th. Finally, HC Wainwright restated a "buy" rating and set a $18.00 price objective on shares of Enanta Pharmaceuticals in a report on Tuesday, February 11th. One analyst has rated the stock with a sell rating, one has issued a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Enanta Pharmaceuticals has an average rating of "Moderate Buy" and a consensus price target of $17.25.

Enanta Pharmaceuticals Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.